Matrix Delivery Transdermal 17β-Estradiol for the Prevention of Bone Loss in Postmenopausal Women

[1]  S. Cummings,et al.  Epidemiology and predictors of fractures associated with osteoporosis. , 1997, The American journal of medicine.

[2]  B. Wren.  Menorest: a clinical overview. , 1996, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[3]  Y Hochberg,et al.  Multiple test procedures for dose finding. , 1996, Biometrics.

[4]  S. Evans,et al.  Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post‐menopausal ages , 1996, Clinical endocrinology.

[5]  A. Genazzani,et al.  Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study. , 1995, Maturitas.

[6]  J. Studd,et al.  The dose–response of percutaneous oestradiol implants on the skeletons of postmenopausal women , 1994, British journal of obstetrics and gynaecology.

[7]  C. Christiansen,et al.  Skeletal osteoporosis , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  B. Riggs,et al.  Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. , 1993, American journal of obstetrics and gynecology.

[9]  J. Balfour,et al.  Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. , 1991, Drugs.

[10]  E. Adashi,et al.  Current status and future prospects of transdermal estrogen replacement therapy. , 1990 .

[11]  H. Genant,et al.  Estrogens in the prevention of osteoporosis in postmenopausal women. , 1989, American journal of obstetrics and gynecology.

[12]  S. Adami,et al.  Transdermal estradiol in the treatment of postmenopausal bone loss. , 1989, Bone and mineral.

[13]  R. Peyron,et al.  Preventive effects of transdermal administration of 17 beta-estradiol on postmenopausal bone loss: a 2-year prospective study. , 1989, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[14]  L. Melton,et al.  Involutional osteoporosis. , 1986, The New England journal of medicine.

[15]  H. Genant,et al.  Long-term estrogen replacement therapy prevents bone loss and fractures. , 1985, Annals of internal medicine.

[16]  C. Christiansen,et al.  BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPY , 1981, The Lancet.

[17]  C. Christiansen,et al.  Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal females , 1971, European journal of clinical investigation.

[18]  R. Recker,et al.  Menopausal changes in bone remodeling. , 1978, The Journal of laboratory and clinical medicine.

[19]  R. Lindsay,et al.  LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN EVIDENCE FOR AN INCREASED BONE MASS AFTER DELAYED ONSET OF ŒSTROGEN TREATMENT , 1976, The Lancet.